Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"MeiraGTx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MeiraGTx to Present Data from Ongoing Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa at AAO 2020 Virtual Meeting","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Janssen's RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with X-Linked Retinitis Pigmentosa","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Late-Breaking Phase 1\/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$415.0 million","upfrontCash":"$350.0 million","newsHeadline":"MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by MeiraGTx

    Menu

    MeiraGTx

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              MeiraGTx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

              Details:

              Under the agreement, Janssen gains the remaining interests in investigational gene therapy AAV5-RPGR (botaretigene sparoparvovec) for the treatment of X-linked retinitis pigmentosa.

              Lead Product(s): Botaretigene Sparoparvovec

              Therapeutic Area: Genetic Disease Product Name: AAV5-RPGR

              Highest Development Status: Phase III Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

              Deal Size: $415.0 million Upfront Cash: $350.0 million

              Deal Type: Agreement December 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MeiraGTx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities

              Details:

              Sanofi will receive a right of first negotiation for the use of MeiraGTx’s Riboswitch gene regulation technology for certain Immunology and Inflammation and CNS targets, including AAV-AQP1, a gene therapy for xerostomia caused by Sjogren's syndrome.

              Lead Product(s): AAV-AQP1

              Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: AAV-AQP1

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Sanofi

              Deal Size: $30.0 million Upfront Cash: Undisclosed

              Deal Type: Financing October 30, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MeiraGTx

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients ...

              Details:

              Treatment with botaretigene sparoparvovec was found to have an acceptable safety profile and efficacy assessments in this proof-of-concept study demonstrated improvements in retinal sensitivity, visual function and functional vision.

              Lead Product(s): Botaretigene Sparoparvovec

              Therapeutic Area: Genetic Disease Product Name: AAV-RPGR

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MeiraGTx

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Janssen's RPGR Gene Therapy Shows Statistically Significant and Continued Vision Improvement in Patients with X-Linked Retinitis Pigmentosa

              Details:

              One-year findings support advancement into Phase 3 and include significant functional vision improvements observed in the time taken to walk through a vision-guided mobility maze at nine months.

              Lead Product(s): AAV2/5-RPGR

              Therapeutic Area: Genetic Disease Product Name: AAV-RPGR

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Recipient: Johnson & Johnson Innovative Medicine

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MeiraGTx

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MeiraGTx to Present Data from Ongoing Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa at AAO 2020 Virtual Meeting

              Details:

              Ongoing Phase 1/2 MGT009 clinical trial demonstrated AAV-RPGR was generally well tolerated and produced significant improvement in vision, including improvement in retinal sensitivity and vision-guided mobility, in the dose escalation phase of the trial.

              Lead Product(s): AAV2/5-RPGR

              Therapeutic Area: Genetic Disease Product Name: Undisclosed

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY